BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 10916757)

  • 1. Anti-tumor activity of K1-LysPE38QQR, an immunotoxin targeting mesothelin, a cell-surface antigen overexpressed in ovarian cancer and malignant mesothelioma.
    Hassan R; Viner JL; Wang QC; Margulies I; Kreitman RJ; Pastan I
    J Immunother; 2000; 23(4):473-9. PubMed ID: 10916757
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bivalent disulfide-stabilized fragment variable immunotoxin directed against mesotheliomas and ovarian cancer.
    Bera TK; Williams-Gould J; Beers R; Chowdhury P; Pastan I
    Mol Cancer Ther; 2001 Dec; 1(2):79-84. PubMed ID: 12467225
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-Mesothelin Recombinant Immunotoxin Therapy for Colorectal Cancer.
    Cerise A; Bera TK; Liu X; Wei J; Pastan I
    Clin Colorectal Cancer; 2019 Sep; 18(3):192-199.e1. PubMed ID: 31345777
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monovalent immunotoxin containing truncated form of Pseudomonas exotoxin as potent antitumor agent.
    Debinski W; Pastan I
    Cancer Res; 1992 Oct; 52(19):5379-85. PubMed ID: 1394141
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytotoxic activity of the recombinant anti-mesothelin immunotoxin, SS1(dsFv)PE38, towards tumor cell lines established from ascites of patients with peritoneal mesotheliomas.
    Li Q; Verschraegen CF; Mendoza J; Hassan R
    Anticancer Res; 2004; 24(3a):1327-35. PubMed ID: 15274292
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 111Indium-labeled monoclonal antibody K1: biodistribution study in nude mice bearing a human carcinoma xenograft expressing mesothelin.
    Hassan R; Wu C; Brechbiel MW; Margulies I; Kreitman RJ; Pastan I
    Int J Cancer; 1999 Feb; 80(4):559-63. PubMed ID: 9935157
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of B1(Fv)PE38 and B1(dsFv)PE38: single-chain and disulfide-stabilized Fv immunotoxins with increased activity that cause complete remissions of established human carcinoma xenografts in nude mice.
    Benhar I; Pastan I
    Clin Cancer Res; 1995 Sep; 1(9):1023-9. PubMed ID: 9816075
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual B- and T-cell de-immunization of recombinant immunotoxin targeting mesothelin with high cytotoxic activity.
    Mazor R; Onda M; Park D; Addissie S; Xiang L; Zhang J; Hassan R; Pastan I
    Oncotarget; 2016 May; 7(21):29916-26. PubMed ID: 27167198
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Isolation of a high-affinity stable single-chain Fv specific for mesothelin from DNA-immunized mice by phage display and construction of a recombinant immunotoxin with anti-tumor activity.
    Chowdhury PS; Viner JL; Beers R; Pastan I
    Proc Natl Acad Sci U S A; 1998 Jan; 95(2):669-74. PubMed ID: 9435250
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor effects of B3-PE and B3-LysPE40 in a nude mouse model of human breast cancer and the evaluation of B3-PE toxicity in monkeys.
    Pai LH; Batra JK; FitzGerald DJ; Willingham MC; Pastan I
    Cancer Res; 1992 Jun; 52(11):3189-93. PubMed ID: 1591729
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced therapeutic efficacy against an ovarian tumor xenograft of immunotoxins used in conjunction with recombinant alpha-interferon.
    Pearson JW; Hedrick E; Fogler WE; Bull RL; Ferris DK; Riggs CW; Wiltrout RH; Sivam G; Morgan AC; Groves E
    Cancer Res; 1990 Oct; 50(19):6379-88. PubMed ID: 2144790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antitumor activity in mice of an immunotoxin made with anti-transferrin receptor and a recombinant form of Pseudomonas exotoxin.
    Batra JK; Jinno Y; Chaudhary VK; Kondo T; Willingham MC; FitzGerald DJ; Pastan I
    Proc Natl Acad Sci U S A; 1989 Nov; 86(21):8545-9. PubMed ID: 2510169
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel high-affinity human monoclonal antibody to mesothelin.
    Ho M; Feng M; Fisher RJ; Rader C; Pastan I
    Int J Cancer; 2011 May; 128(9):2020-30. PubMed ID: 20635390
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front-line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen 125.
    Hassan R; Sharon E; Thomas A; Zhang J; Ling A; Miettinen M; Kreitman RJ; Steinberg SM; Hollevoet K; Pastan I
    Cancer; 2014 Nov; 120(21):3311-9. PubMed ID: 24989332
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted therapy against human lung cancer in nude mice by high-affinity recombinant antimesothelin single-chain Fv immunotoxin.
    Fan D; Yano S; Shinohara H; Solorzano C; Van Arsdall M; Bucana CD; Pathak S; Kruzel E; Herbst RS; Onn A; Roach JS; Onda M; Wang QC; Pastan I; Fidler IJ
    Mol Cancer Ther; 2002 Jun; 1(8):595-600. PubMed ID: 12479219
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant single-chain and disulfide-stabilized Fv-immunotoxins that cause complete regression of a human colon cancer xenograft in nude mice.
    Reiter Y; Wright AF; Tonge DW; Pastan I
    Int J Cancer; 1996 Jul; 67(1):113-23. PubMed ID: 8690511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved binding and antitumor activity of a recombinant anti-erbB2 immunotoxin by disulfide stabilization of the Fv fragment.
    Reiter Y; Brinkmann U; Jung SH; Lee B; Kasprzyk PG; King CR; Pastan I
    J Biol Chem; 1994 Jul; 269(28):18327-31. PubMed ID: 7913461
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel immunotoxin recognising the epithelial glycoprotein-2 has potent antitumoural activity on chemotherapy-resistant lung cancer.
    Zimmermann S; Wels W; Froesch BA; Gerstmayer B; Stahel RA; Zangemeister-Wittke U
    Cancer Immunol Immunother; 1997 Mar; 44(1):1-9. PubMed ID: 9111578
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anticancer Effects of Mesothelin-Targeted Immunotoxin Therapy Are Regulated by Tyrosine Kinase DDR1.
    Ali-Rahmani F; FitzGerald DJ; Martin S; Patel P; Prunotto M; Ormanoglu P; Thomas C; Pastan I
    Cancer Res; 2016 Mar; 76(6):1560-8. PubMed ID: 26719540
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Engineered Anti-GPC3 Immunotoxin, HN3-ABD-T20, Produces Regression in Mouse Liver Cancer Xenografts Through Prolonged Serum Retention.
    Fleming BD; Urban DJ; Hall MD; Longerich T; Greten TF; Pastan I; Ho M
    Hepatology; 2020 May; 71(5):1696-1711. PubMed ID: 31520528
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.